AtaGenix Laboratories
AtaGenix Laboratories
AtaGenix specializes in high-efficiency protein expression using CHO and HEK293 cells with advanced transient transfection technologies like XtenCHO and FreeStyle CHO. We offer end-to-end services, ensuring near-native recombinant proteins for antigen preparation, antibody discovery, and biopharmaceutical development.
Professional and Efficient
10+ years of experience, 10,000+ antibodies/year, 300+ monoclonals.
High-Quality Assurance
ISO9001-certified, 100,000-grade cleanrooms, guaranteed purity.
Scalable Manufacturing Capability
2,000L+ annual capacity, from trials to large-scale production.
AtaGenix offers a fully integrated system for CHO and HEK293 cell expression, featuring proprietary media, transfection reagents, and purification workflows like ion exchange and gel filtration. This platform ensures high-yield protein and antibody production with two key advantages:
A 2017 study developed a high-affinity anti-HE4 monoclonal antibody (9C3) using AtaGenix’s advanced mammalian expression and hybridoma platforms. This breakthrough enhances ovarian cancer diagnostics by targeting the HE4 biomarker with high specificity, offering potential for early detection and therapy.
This article highlights a 2021 Small Methods study that identified immunogenic peptides in the SARS-CoV-2 spike protein and isolated neutralizing monoclonal antibodies from COVID-19 patients. The research pinpointed key RBM epitopes (S431-454, S470-486, S501-515), with S470-486 emerging as an immunodominant target for diagnostics and therapeutics. Using phage display and ScFv libraries, the study validated epitope mapping and antibody functionality. Supported by AtaGenix’s expertise in phage display, protein expression, and assay development, this breakthrough offers a scalable approach for combating emerging viral pathogens, updated as of August 24, 2025.
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
